8 Mar 2022 12:30
REDX PHARMA PLC
("Redx" or "the Company")
Result of Annual General Meeting
Alderley Park, 8 March 2022 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announces that its Annual General Meeting was held at 11am on 8 March 2022, with all resolutions passed by substantial majorities.
The table below sets out the details of the votes put to shareholders
Resolution number | Resolution name | Number of votes for & discretionary | % of votes for & discretionary | Number of votes against | % of votes against | % of votes witheld | Total votes cast (including withheld) |
1 | Receive the Company's annual accounts | 249,366,792 | 94.84% | 13,571,429 | 5.16% | 0.00% | 262,939,628 |
2 | Re-appoint Ernst & Young as auditors | 262,938,221 | 100% | 0 | 0.00% | 0.00% | 262,939,628 |
3 | Elect Natalie Berner as a director | 262,938,221 | 100% | 0 | 0.00% | 0.00% | 262,939,628 |
4 | Elect Dr Jane Griffiths as a director | 262,938,221 | 100% | 0 | 0.00% | 0.00% | 262,939,628 |
5 | Elect Dr Robert Scott as a director | 262,938,221 | 100% | 0 | 0.00% | 0.00% | 262,939,628 |
6 | Re-elect Dr Thomas Burt as a director | 262,938,221 | 100% | 0 | 0.00% | 0.00% | 262,939,628 |
7 | Re-elect Sarah Gordon Wild as a director | 249,366,792 | 94.84% | 13,571,429 | 5.16% | 0.00% | 262,939,628 |
8 | Re-elect Peter Presland as a director | 249,366,792 | 94.84% | 13,571,429 | 5.16% | 0.00% | 262,939,628 |
9 | Authorise the directors to allot shares | 262,936,468 | 100% | 853 | 0.00% | 0.00% | 262,939,628 |
10 | Disapply pre-emption rights | 262,923,468 | 99.99% | 13,853 | 0.01% | 0.00% | 262,939,628 |
For further information, please contact: | |
Redx Pharma Plc ir@redxpharma.com
UK Headquarters Lisa Anson, Chief Executive Officer | T: +44 (0)1625 469 918
|
US Office Peter Collum, Chief Financial Officer | |
SPARK Advisory Partners (Nominated Adviser) | T: +44 (0)203 368 3550 |
Matt Davis/ Adam Dawes | |
WG Partners LLP (Joint Broker) | T: +44 (0)203 705 9330 |
Claes Spång/ David Wilson/Satheesh Nadarajah | |
Panmure Gordon (UK) Limited (Joint Broker) | T: +44 (0)207 886 2500 |
Rupert Dearden/ Freddy Crossley/ Emma Earl | |
FTI Consulting | T: +44 (0)203 727 1000 |
Simon Conway/ Ciara Martin |
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's selective ROCK2 inhibitor product candidate, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical trial in June 2021. Initial results were reported in October 2021, with full Phase 1 results expected in 2022.
The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals.
To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/